Form 4: PMV Pharmaceuticals CFO Sells Shares to Cover Tax Obligations from RSU Vesting

PMV Pharmaceuticals' Chief Financial Officer, Michael Carulli, sold 28,249 shares of common stock for $1.0647 per share to satisfy tax obligations related to the vesting of restricted stock units.

Summary

• Michael Carulli, Chief Financial Officer of PMV Pharmaceuticals, Inc. (PMVP), reported a transaction involving the sale of company common stock.
• On July 1, 2025, Mr. Carulli sold 28,249 shares of PMV Pharmaceuticals common stock.
• The shares were sold at a price of $1.0647 per share.
• The purpose of the sale was to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units (RSUs).
• Following this transaction, Mr. Carulli directly beneficially owns 60,146 shares of PMV Pharmaceuticals common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves an insider selling shares, the stated reason (tax obligations from RSU vesting) is a common and non-discretionary event, not typically indicative of a negative outlook on the company.

Positives

• The sale was explicitly stated to be for satisfying tax obligations related to the vesting of restricted stock units, indicating a non-discretionary transaction.
• The vesting of restricted stock units implies that performance or tenure conditions were met, which is generally a positive indicator for employee incentives and retention.

Negatives

• The transaction resulted in a reduction of the Chief Financial Officer's direct beneficial ownership in the company by 28,249 shares.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its tax-related nature suggests it is not a signal of management's lack of confidence in the company's future.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard part of executive compensation, demonstrating the company's incentive programs are functioning.

Key Dates

Keywords

PMV Pharmaceuticals, PMVP, Michael Carulli, Chief Financial Officer, CFO, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Obligations, Form 4, SEC Filing, Rule 10b5-1